However, most patients with HR+HER2– disease did not achieve a pCR and IO agents carry substantial risk of long-term immune-related toxicities and represent a major health care cost.16 This has motivated us to develop more accurate predictors of IO benefit in HR+HER2– breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.